GAMMA Investing LLC Increases Stock Position in Integer Holdings Corporation $ITGR

GAMMA Investing LLC boosted its stake in Integer Holdings Corporation (NYSE:ITGR) by 20.2% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 796 shares of the medical equipment provider’s stock after acquiring an additional 134 shares during the period. GAMMA Investing LLC’s holdings in Integer were worth $98,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Vaughan Nelson Investment Management L.P. acquired a new position in Integer in the first quarter valued at $33,337,000. Nuveen LLC acquired a new position in Integer in the first quarter valued at $17,634,000. Millennium Management LLC increased its stake in shares of Integer by 2,408.8% during the first quarter. Millennium Management LLC now owns 123,132 shares of the medical equipment provider’s stock worth $14,531,000 after acquiring an additional 118,224 shares during the period. The Manufacturers Life Insurance Company increased its stake in shares of Integer by 40.2% during the first quarter. The Manufacturers Life Insurance Company now owns 213,741 shares of the medical equipment provider’s stock worth $25,224,000 after acquiring an additional 61,273 shares during the period. Finally, Assenagon Asset Management S.A. acquired a new position in shares of Integer during the second quarter worth about $6,314,000. 99.29% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on ITGR. Wall Street Zen upgraded shares of Integer from a “hold” rating to a “buy” rating in a research note on Saturday, August 30th. Wells Fargo & Company dropped their price target on shares of Integer from $152.00 to $132.00 and set an “overweight” rating on the stock in a research note on Friday, July 25th. Truist Financial dropped their price target on shares of Integer from $145.00 to $137.00 and set a “buy” rating on the stock in a research note on Friday, July 25th. Finally, Raymond James Financial dropped their price target on shares of Integer from $150.00 to $143.00 and set an “outperform” rating on the stock in a research note on Friday, July 25th. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat.com, Integer has a consensus rating of “Buy” and an average price target of $139.57.

Integer Stock Performance

Shares of ITGR opened at $102.93 on Thursday. The company has a debt-to-equity ratio of 0.72, a quick ratio of 2.18 and a current ratio of 3.41. The company has a market capitalization of $3.61 billion, a price-to-earnings ratio of 45.35, a PEG ratio of 0.82 and a beta of 0.97. Integer Holdings Corporation has a 1 year low of $99.73 and a 1 year high of $146.36. The company’s 50 day simple moving average is $105.79 and its 200 day simple moving average is $114.30.

Integer (NYSE:ITGR) last posted its quarterly earnings results on Thursday, July 24th. The medical equipment provider reported $1.55 earnings per share for the quarter, missing analysts’ consensus estimates of $1.57 by ($0.02). The company had revenue of $476.00 million for the quarter, compared to analysts’ expectations of $464.37 million. Integer had a return on equity of 12.27% and a net margin of 4.61%.The business’s revenue for the quarter was up 11.4% on a year-over-year basis. During the same period in the prior year, the business earned $1.30 EPS. Integer has set its FY 2025 guidance at 6.250-6.510 EPS. On average, sell-side analysts predict that Integer Holdings Corporation will post 6.01 EPS for the current year.

About Integer

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.